Loading clinical trials...
Loading clinical trials...
An Open-label, Randomized Phase 3 Study of the Efficacy and Tolerability of Linifanib (ABT-869) Versus Sorafenib in Subjects With Advanced Hepatocellular Carcinoma (HCC)
Conditions
Interventions
ABT-869
Sorafenib
Locations
163
United States
Site Reference ID/Investigator# 23247
Beverly Hills, California, United States
Site Reference ID/Investigator# 23608
LaVerne, California, United States
Site Reference ID/Investigator# 23852
Orange, California, United States
Site Reference ID/Investigator# 40162
Orange, California, United States
Site Reference ID/Investigator# 23254
Newark, Delaware, United States
Site Reference ID/Investigator# 23253
Gainesville, Georgia, United States
Start Date
January 1, 2010
Primary Completion Date
July 1, 2012
Completion Date
July 1, 2012
Last Updated
September 10, 2012
NCT07118202
NCT06707233
NCT05911633
NCT06187961
NCT06571396
NCT06561399
Lead Sponsor
Abbott
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions